GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.

Intraductal papillary neoplasms of the bile duct (IPNB) shows favorable prognosis and is regarded as a biliary counterpart of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Although activating point mutations of GNAS at codon 201 have been detected in approximately two thirds of IPM...

Full description

Bibliographic Details
Main Authors: Motoko Sasaki, Takashi Matsubara, Takeo Nitta, Yasunori Sato, Yasuni Nakanuma
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3847161?pdf=render
id doaj-55ce8cf92d2e4a629e5b69635173da0a
record_format Article
spelling doaj-55ce8cf92d2e4a629e5b69635173da0a2020-11-25T00:42:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01812e8170610.1371/journal.pone.0081706GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.Motoko SasakiTakashi MatsubaraTakeo NittaYasunori SatoYasuni NakanumaIntraductal papillary neoplasms of the bile duct (IPNB) shows favorable prognosis and is regarded as a biliary counterpart of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Although activating point mutations of GNAS at codon 201 have been detected in approximately two thirds of IPMNs of the pancreas, there have been few studies on GNAS mutations in IPNBs. This study investigates the status of GNAS and KRAS mutations and their association with clinicopathological factors in IPNBs. We examined the status of GNAS mutation at codon 201 and KRAS mutation at codon 12&13, degree of mucin production and immunohistochemical expressions of MUC mucin core proteins in 29 patients (M/F = 15/14) with IPNB in intrahepatic and perihilar bile ducts (perihilar IPNB) and 6 patients (M/F = 5/1) with IPNB in distal bile ducts (distal IPNB). GNAS mutations and KRAS mutations were detected in 50% and 46.2% of IPNBs, respectively. There was no significant correlation between the status of GNAS mutation and clinicopathological factors in IPNBs, whereas, the status of KRAS mutation was significantly inversely correlated with the degree of MUC2 expression in IPNBs (p<0.05). All IPNBs with GNAS mutation only showed high-mucin production. Degree of mucin production was significantly higher in perihilar IPNBs than distal IPNBs (p<0.05). MUC2 and MUC5AC expression was significantly higher in IPNBs with high-mucin production than those with low-mucin production (p<0.01 and p<0.05, respectively). In conclusions, this study firstly disclosed frequent GNAS mutations in IPNBs, similarly to IPMNs. This may suggest a common histopathogenesis of IPNBs and IPMNs. The status of KRAS mutations was inversely correlated to MUC2 expression and this may suggest heterogeneous properties of IPNBs. IPNBs with high-mucin production are characterized by perihilar location and high expression of MUC2 and MUC5AC, irrespective of the status of GNAS and KRAS mutations.http://europepmc.org/articles/PMC3847161?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Motoko Sasaki
Takashi Matsubara
Takeo Nitta
Yasunori Sato
Yasuni Nakanuma
spellingShingle Motoko Sasaki
Takashi Matsubara
Takeo Nitta
Yasunori Sato
Yasuni Nakanuma
GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
PLoS ONE
author_facet Motoko Sasaki
Takashi Matsubara
Takeo Nitta
Yasunori Sato
Yasuni Nakanuma
author_sort Motoko Sasaki
title GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
title_short GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
title_full GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
title_fullStr GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
title_full_unstemmed GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct.
title_sort gnas and kras mutations are common in intraductal papillary neoplasms of the bile duct.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2013-01-01
description Intraductal papillary neoplasms of the bile duct (IPNB) shows favorable prognosis and is regarded as a biliary counterpart of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Although activating point mutations of GNAS at codon 201 have been detected in approximately two thirds of IPMNs of the pancreas, there have been few studies on GNAS mutations in IPNBs. This study investigates the status of GNAS and KRAS mutations and their association with clinicopathological factors in IPNBs. We examined the status of GNAS mutation at codon 201 and KRAS mutation at codon 12&13, degree of mucin production and immunohistochemical expressions of MUC mucin core proteins in 29 patients (M/F = 15/14) with IPNB in intrahepatic and perihilar bile ducts (perihilar IPNB) and 6 patients (M/F = 5/1) with IPNB in distal bile ducts (distal IPNB). GNAS mutations and KRAS mutations were detected in 50% and 46.2% of IPNBs, respectively. There was no significant correlation between the status of GNAS mutation and clinicopathological factors in IPNBs, whereas, the status of KRAS mutation was significantly inversely correlated with the degree of MUC2 expression in IPNBs (p<0.05). All IPNBs with GNAS mutation only showed high-mucin production. Degree of mucin production was significantly higher in perihilar IPNBs than distal IPNBs (p<0.05). MUC2 and MUC5AC expression was significantly higher in IPNBs with high-mucin production than those with low-mucin production (p<0.01 and p<0.05, respectively). In conclusions, this study firstly disclosed frequent GNAS mutations in IPNBs, similarly to IPMNs. This may suggest a common histopathogenesis of IPNBs and IPMNs. The status of KRAS mutations was inversely correlated to MUC2 expression and this may suggest heterogeneous properties of IPNBs. IPNBs with high-mucin production are characterized by perihilar location and high expression of MUC2 and MUC5AC, irrespective of the status of GNAS and KRAS mutations.
url http://europepmc.org/articles/PMC3847161?pdf=render
work_keys_str_mv AT motokosasaki gnasandkrasmutationsarecommoninintraductalpapillaryneoplasmsofthebileduct
AT takashimatsubara gnasandkrasmutationsarecommoninintraductalpapillaryneoplasmsofthebileduct
AT takeonitta gnasandkrasmutationsarecommoninintraductalpapillaryneoplasmsofthebileduct
AT yasunorisato gnasandkrasmutationsarecommoninintraductalpapillaryneoplasmsofthebileduct
AT yasuninakanuma gnasandkrasmutationsarecommoninintraductalpapillaryneoplasmsofthebileduct
_version_ 1725282261558886400